Table 3 Characteristics of the experts that participated in the scenario drafting questionnaire (n = 29)
Number of respondents | 29 (100%) |
Function | |
Medical oncologist | 22 (76%) |
Director | 3 (10%) |
Head cell production | 1 (3%) |
Consultant | 1 (3%) |
Clinical and translational research | 2 (7%) |
Mean experience with melanoma, years (range) | 16.38 (1–35) |
Mean experience with TIL therapy, years (range) | 2.72 (0–20) |
Level of familiarity with TIL therapy | |
Unfamiliar | 0 (0%) |
Accidentally familiar | 3 (10%) |
Familiar | 15 (52%) |
Former expert | 3 (10%) |
Expert | 8 (28%) |
Employed in: | |
Australia | 1 (3%) |
Belgium | 1 (3%) |
Denmark | 2 (7%) |
Germany | 3 (10%) |
Israel | 1 (3%) |
Italy | 1 (3%) |
Netherlands | 14 (48%) |
Poland | 1 (3%) |
Portugal | 1 (3%) |
Spain | 1 (3%) |
UK | 1 (3%) |
US | 1 (3%) |
N/A | 1 (3%) |